Lunai Bioworks (LNAI) EPS (Basic) Growth (1y) (2012 - 2026)
Lunai Bioworks (LNAI) EPS (Basic) Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | -16.29% |
| 10 | Lunai Bioworks | 6.94 Mn | 3.78 Mn | 20,942.00 | 76.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.34% |
| Dec 31, 2025 | 71.15% |
| Sep 30, 2025 | 95.54% |
| Jun 30, 2025 | -350.36% |
| Mar 31, 2025 | 94.43% |
| Dec 31, 2024 | 58.41% |
| Sep 30, 2024 | -139.97% |
| Jun 30, 2024 | 58.76% |
| Mar 31, 2024 | -522.43% |
| Dec 31, 2023 | 14.06% |
| Sep 30, 2023 | -1.82% |
| Jun 30, 2023 | 76.00% |
| Mar 31, 2023 | 34.36% |
| Dec 31, 2022 | 36.17% |
| Sep 30, 2022 | 29.91% |
| Jun 30, 2022 | -366.67% |
| Mar 31, 2022 | -36.74% |
| Dec 31, 2021 | -100.14% |
| Sep 30, 2021 | -287.74% |
| Jun 30, 2021 | -316.16% |